| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 61 | 2023 | 955 | 11.180 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 33 | 2023 | 333 | 9.480 |
Why?
|
| Mycobacterium abscessus | 14 | 2023 | 98 | 5.660 |
Why?
|
| Neutrophils | 34 | 2023 | 1176 | 3.500 |
Why?
|
| Nontuberculous Mycobacteria | 19 | 2023 | 204 | 3.240 |
Why?
|
| Pseudomonas aeruginosa | 15 | 2022 | 298 | 2.980 |
Why?
|
| Pseudomonas Infections | 12 | 2022 | 184 | 2.180 |
Why?
|
| Azithromycin | 8 | 2021 | 80 | 2.020 |
Why?
|
| Anti-Bacterial Agents | 21 | 2023 | 1477 | 1.750 |
Why?
|
| Mycobacterium | 5 | 2023 | 103 | 1.640 |
Why?
|
| Tobramycin | 7 | 2021 | 47 | 1.520 |
Why?
|
| Cross Infection | 3 | 2021 | 197 | 1.420 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 11 | 2020 | 287 | 1.270 |
Why?
|
| Biofilms | 6 | 2014 | 223 | 1.030 |
Why?
|
| Lung | 21 | 2023 | 3558 | 0.970 |
Why?
|
| Sputum | 9 | 2022 | 285 | 0.940 |
Why?
|
| Bacteriophages | 2 | 2023 | 75 | 0.920 |
Why?
|
| Mycobacterium Infections | 4 | 2022 | 61 | 0.920 |
Why?
|
| C-Reactive Protein | 2 | 2018 | 362 | 0.890 |
Why?
|
| Interferons | 2 | 2016 | 151 | 0.860 |
Why?
|
| Pneumonia | 5 | 2023 | 567 | 0.860 |
Why?
|
| Humans | 100 | 2023 | 114624 | 0.800 |
Why?
|
| Respiratory Function Tests | 4 | 2020 | 522 | 0.800 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2022 | 268 | 0.760 |
Why?
|
| Lipopolysaccharides | 13 | 2020 | 821 | 0.760 |
Why?
|
| Mitogen-Activated Protein Kinases | 9 | 2004 | 278 | 0.690 |
Why?
|
| Aztreonam | 2 | 2016 | 8 | 0.670 |
Why?
|
| Microbial Viability | 5 | 2021 | 79 | 0.670 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 6 | 2000 | 172 | 0.670 |
Why?
|
| Quinolones | 2 | 2019 | 97 | 0.650 |
Why?
|
| Aminophenols | 2 | 2019 | 112 | 0.650 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 1518 | 0.630 |
Why?
|
| Infection Control | 1 | 2019 | 135 | 0.610 |
Why?
|
| Fomites | 1 | 2017 | 7 | 0.590 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 195 | 0.580 |
Why?
|
| Gene Expression Regulation | 6 | 2020 | 2319 | 0.560 |
Why?
|
| Glucose Tolerance Test | 2 | 2016 | 343 | 0.560 |
Why?
|
| Forced Expiratory Volume | 10 | 2021 | 475 | 0.560 |
Why?
|
| Lung Diseases | 3 | 2016 | 701 | 0.520 |
Why?
|
| Extracellular Space | 2 | 2018 | 116 | 0.510 |
Why?
|
| Neutrophil Activation | 3 | 2013 | 94 | 0.510 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2017 | 493 | 0.500 |
Why?
|
| Adult | 32 | 2023 | 30528 | 0.500 |
Why?
|
| Glucose Intolerance | 1 | 2016 | 136 | 0.490 |
Why?
|
| Sildenafil Citrate | 1 | 2014 | 57 | 0.470 |
Why?
|
| Metalloproteases | 1 | 2014 | 37 | 0.470 |
Why?
|
| Leukocyte Elastase | 1 | 2014 | 79 | 0.470 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 2021 | 63 | 0.460 |
Why?
|
| Deoxyribonucleases | 2 | 2011 | 21 | 0.460 |
Why?
|
| Genetic Testing | 2 | 2017 | 379 | 0.460 |
Why?
|
| Male | 37 | 2022 | 55555 | 0.450 |
Why?
|
| Quorum Sensing | 1 | 2014 | 71 | 0.450 |
Why?
|
| Virulence Factors | 1 | 2014 | 139 | 0.430 |
Why?
|
| Treatment Outcome | 10 | 2019 | 9084 | 0.430 |
Why?
|
| Wound Infection | 1 | 2013 | 30 | 0.420 |
Why?
|
| Female | 42 | 2021 | 59466 | 0.410 |
Why?
|
| Mycobacterium avium Complex | 4 | 2023 | 92 | 0.400 |
Why?
|
| Superoxides | 6 | 2018 | 214 | 0.390 |
Why?
|
| Cellular Structures | 1 | 2011 | 3 | 0.390 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2011 | 5 | 0.380 |
Why?
|
| RNA, Messenger | 3 | 2022 | 2552 | 0.380 |
Why?
|
| Eye Infections, Bacterial | 1 | 2011 | 26 | 0.370 |
Why?
|
| Respiratory Tract Infections | 4 | 2017 | 319 | 0.370 |
Why?
|
| Actins | 5 | 2009 | 381 | 0.360 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2022 | 300 | 0.350 |
Why?
|
| Chemotaxis, Leukocyte | 5 | 2006 | 130 | 0.350 |
Why?
|
| Prospective Studies | 8 | 2023 | 6217 | 0.350 |
Why?
|
| Mycobacterium avium | 2 | 2023 | 21 | 0.350 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 900 | 0.350 |
Why?
|
| Disease Progression | 6 | 2019 | 2380 | 0.350 |
Why?
|
| Drug Interactions | 3 | 2016 | 338 | 0.340 |
Why?
|
| Chloride Channel Agonists | 2 | 2020 | 62 | 0.340 |
Why?
|
| Peptides | 3 | 2011 | 848 | 0.340 |
Why?
|
| DNA | 3 | 2018 | 1352 | 0.340 |
Why?
|
| Pneumonia, Bacterial | 4 | 2016 | 106 | 0.340 |
Why?
|
| Burns | 1 | 2013 | 237 | 0.330 |
Why?
|
| Mutation | 7 | 2020 | 3344 | 0.330 |
Why?
|
| Cytokines | 11 | 2018 | 1840 | 0.320 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 10 | 2011 | 260 | 0.320 |
Why?
|
| Young Adult | 11 | 2020 | 10455 | 0.320 |
Why?
|
| RNA Precursors | 2 | 2017 | 136 | 0.320 |
Why?
|
| Neutrophil Infiltration | 6 | 2014 | 96 | 0.320 |
Why?
|
| Coinfection | 4 | 2020 | 120 | 0.300 |
Why?
|
| Antitubercular Agents | 4 | 2021 | 169 | 0.300 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 2537 | 0.300 |
Why?
|
| Cell Separation | 3 | 2016 | 291 | 0.300 |
Why?
|
| Risk Factors | 7 | 2021 | 8628 | 0.300 |
Why?
|
| Biomarkers | 7 | 2022 | 3408 | 0.300 |
Why?
|
| Blood Glucose | 1 | 2016 | 1819 | 0.290 |
Why?
|
| Staphylococcus aureus | 1 | 2011 | 385 | 0.290 |
Why?
|
| Protein C | 2 | 2005 | 45 | 0.290 |
Why?
|
| Survivors | 1 | 2010 | 411 | 0.280 |
Why?
|
| Macrophages, Alveolar | 6 | 2020 | 347 | 0.270 |
Why?
|
| Colorado | 4 | 2022 | 4099 | 0.250 |
Why?
|
| Signal Transduction | 11 | 2020 | 4509 | 0.240 |
Why?
|
| Drug Monitoring | 2 | 2016 | 184 | 0.230 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 295 | 0.230 |
Why?
|
| Inflammation | 10 | 2022 | 2478 | 0.230 |
Why?
|
| Administration, Inhalation | 4 | 2022 | 641 | 0.220 |
Why?
|
| Leukocyte Disorders | 2 | 2014 | 11 | 0.220 |
Why?
|
| Case-Control Studies | 6 | 2021 | 3003 | 0.220 |
Why?
|
| Phagocytosis | 3 | 2023 | 350 | 0.220 |
Why?
|
| Dust | 1 | 2023 | 84 | 0.220 |
Why?
|
| Leukocytes | 2 | 2018 | 276 | 0.210 |
Why?
|
| Phage Therapy | 1 | 2023 | 6 | 0.210 |
Why?
|
| Rifampin | 2 | 2021 | 68 | 0.210 |
Why?
|
| Morbidity | 3 | 2019 | 280 | 0.210 |
Why?
|
| Mice | 21 | 2023 | 14860 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2022 | 951 | 0.200 |
Why?
|
| Double-Blind Method | 3 | 2020 | 1660 | 0.200 |
Why?
|
| Cell Adhesion | 6 | 2011 | 431 | 0.200 |
Why?
|
| Antimalarials | 1 | 2022 | 24 | 0.200 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 770 | 0.190 |
Why?
|
| Molybdenum | 1 | 2021 | 8 | 0.190 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 440 | 0.190 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 246 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 1999 | 113 | 0.190 |
Why?
|
| Adolescent | 12 | 2021 | 17831 | 0.190 |
Why?
|
| Middle Aged | 12 | 2021 | 26719 | 0.190 |
Why?
|
| Ethambutol | 1 | 2021 | 20 | 0.190 |
Why?
|
| Ciprofloxacin | 2 | 2013 | 23 | 0.190 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 2 | 2000 | 65 | 0.180 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 429 | 0.180 |
Why?
|
| Genome, Bacterial | 1 | 2021 | 106 | 0.180 |
Why?
|
| Rhodospirillaceae | 1 | 2020 | 4 | 0.180 |
Why?
|
| Water | 1 | 2023 | 396 | 0.180 |
Why?
|
| Bacteriological Techniques | 1 | 2021 | 65 | 0.180 |
Why?
|
| Steroid Hydroxylases | 1 | 2020 | 19 | 0.180 |
Why?
|
| Survival Analysis | 3 | 2016 | 1211 | 0.180 |
Why?
|
| Interleukin-8 | 4 | 2020 | 237 | 0.180 |
Why?
|
| Amides | 1 | 2020 | 86 | 0.170 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2018 | 23 | 0.170 |
Why?
|
| Animals | 23 | 2023 | 31695 | 0.170 |
Why?
|
| Functional Residual Capacity | 1 | 2019 | 7 | 0.170 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 311 | 0.170 |
Why?
|
| Complement System Proteins | 1 | 2023 | 283 | 0.170 |
Why?
|
| Pilot Projects | 3 | 2022 | 1372 | 0.170 |
Why?
|
| Colistin | 1 | 2019 | 8 | 0.170 |
Why?
|
| Time Factors | 6 | 2021 | 6112 | 0.160 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 531 | 0.160 |
Why?
|
| Exostoses, Multiple Hereditary | 1 | 1999 | 4 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1796 | 0.160 |
Why?
|
| Pleural Diseases | 1 | 1999 | 20 | 0.160 |
Why?
|
| Ribs | 1 | 1999 | 29 | 0.160 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 138 | 0.160 |
Why?
|
| Toll-Like Receptors | 2 | 2017 | 167 | 0.160 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 307 | 0.160 |
Why?
|
| Drug Combinations | 2 | 2018 | 287 | 0.160 |
Why?
|
| British Columbia | 1 | 2018 | 10 | 0.150 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2018 | 100 | 0.150 |
Why?
|
| Genomics | 4 | 2021 | 635 | 0.150 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2021 | 155 | 0.150 |
Why?
|
| Intracellular Space | 1 | 2018 | 68 | 0.150 |
Why?
|
| Extracellular Traps | 1 | 2018 | 40 | 0.150 |
Why?
|
| Oligonucleotides | 1 | 2018 | 137 | 0.150 |
Why?
|
| Enzyme Activation | 7 | 2008 | 785 | 0.150 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 94 | 0.140 |
Why?
|
| Pyridines | 1 | 2020 | 425 | 0.140 |
Why?
|
| Clofazimine | 1 | 2017 | 14 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 1997 | 14 | 0.140 |
Why?
|
| Databases, Genetic | 1 | 2018 | 206 | 0.140 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 40 | 0.140 |
Why?
|
| Cell Death | 3 | 2016 | 322 | 0.140 |
Why?
|
| Platelet Activating Factor | 1 | 1997 | 90 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 833 | 0.140 |
Why?
|
| Bronchoalveolar Lavage Fluid | 8 | 2015 | 590 | 0.140 |
Why?
|
| Genetic Therapy | 1 | 2018 | 257 | 0.140 |
Why?
|
| Heme Oxygenase-1 | 1 | 2016 | 52 | 0.130 |
Why?
|
| Aged | 8 | 2021 | 19061 | 0.130 |
Why?
|
| Polyarteritis Nodosa | 1 | 1996 | 5 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2017 | 245 | 0.130 |
Why?
|
| Alternative Splicing | 1 | 2017 | 187 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 11 | 2016 | 4689 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 497 | 0.120 |
Why?
|
| Interferon-alpha | 1 | 2016 | 186 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 4894 | 0.120 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 1230 | 0.120 |
Why?
|
| Bacterial Load | 2 | 2015 | 58 | 0.120 |
Why?
|
| Survival Rate | 2 | 2018 | 1644 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 2016 | 211 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 4411 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2021 | 12542 | 0.120 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 36 | 0.120 |
Why?
|
| Computational Biology | 1 | 2018 | 530 | 0.120 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 63 | 0.120 |
Why?
|
| Symptom Flare Up | 3 | 2020 | 38 | 0.120 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 3531 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 811 | 0.110 |
Why?
|
| Cell Movement | 4 | 2013 | 868 | 0.110 |
Why?
|
| Phenotype | 1 | 2021 | 2796 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1997 | 333 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2016 | 953 | 0.110 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2013 | 14 | 0.110 |
Why?
|
| Administration, Intravenous | 3 | 2019 | 124 | 0.110 |
Why?
|
| Thiocyanates | 1 | 2013 | 29 | 0.110 |
Why?
|
| Mass Screening | 2 | 2016 | 1004 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2015 | 1578 | 0.100 |
Why?
|
| NF-kappa B | 6 | 2013 | 638 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2014 | 112 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1430 | 0.100 |
Why?
|
| Leptin | 1 | 2014 | 210 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2013 | 65 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2018 | 585 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2013 | 316 | 0.100 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2016 | 498 | 0.100 |
Why?
|
| Oxidants | 1 | 2013 | 112 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 313 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 336 | 0.100 |
Why?
|
| Comorbidity | 1 | 2016 | 1448 | 0.100 |
Why?
|
| Immunity, Innate | 3 | 2013 | 720 | 0.100 |
Why?
|
| Suspensions | 1 | 2011 | 30 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 740 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2008 | 1139 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2013 | 309 | 0.090 |
Why?
|
| Corneal Ulcer | 1 | 2011 | 14 | 0.090 |
Why?
|
| Epithelium, Corneal | 1 | 2011 | 35 | 0.090 |
Why?
|
| United States | 7 | 2021 | 12176 | 0.090 |
Why?
|
| cdc42 GTP-Binding Protein | 3 | 2006 | 24 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6344 | 0.090 |
Why?
|
| Bacterial Adhesion | 1 | 2011 | 78 | 0.090 |
Why?
|
| Metagenomics | 2 | 2021 | 131 | 0.090 |
Why?
|
| Methacrylates | 1 | 2011 | 106 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2014 | 298 | 0.090 |
Why?
|
| Prognosis | 1 | 2018 | 3328 | 0.090 |
Why?
|
| Viruses | 1 | 2011 | 94 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 1996 | 1015 | 0.090 |
Why?
|
| Species Specificity | 1 | 2011 | 542 | 0.090 |
Why?
|
| Macrophages | 4 | 2023 | 1261 | 0.080 |
Why?
|
| Rabbits | 1 | 2011 | 733 | 0.080 |
Why?
|
| Allergens | 2 | 2003 | 413 | 0.080 |
Why?
|
| Antioxidants | 1 | 2013 | 530 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 445 | 0.080 |
Why?
|
| Age Distribution | 1 | 2010 | 342 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2010 | 337 | 0.080 |
Why?
|
| Imidazoles | 3 | 2000 | 208 | 0.080 |
Why?
|
| Lipids | 1 | 2013 | 580 | 0.080 |
Why?
|
| Sinusitis | 2 | 2014 | 174 | 0.080 |
Why?
|
| Respiratory Mucosa | 2 | 2008 | 251 | 0.080 |
Why?
|
| Aminopyridines | 2 | 2018 | 81 | 0.080 |
Why?
|
| Leukocyte Count | 3 | 2013 | 293 | 0.080 |
Why?
|
| Pneumonia, Viral | 1 | 2014 | 338 | 0.080 |
Why?
|
| Age of Onset | 1 | 2010 | 445 | 0.080 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2008 | 9 | 0.080 |
Why?
|
| Klebsiella Infections | 1 | 2008 | 23 | 0.080 |
Why?
|
| Spirometry | 1 | 2008 | 224 | 0.070 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 60 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2017 | 447 | 0.070 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 61 | 0.070 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 1999 | 81 | 0.070 |
Why?
|
| HMGB1 Protein | 1 | 2007 | 48 | 0.070 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2005 | 144 | 0.070 |
Why?
|
| ROC Curve | 1 | 2008 | 442 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2762 | 0.070 |
Why?
|
| Endotoxins | 2 | 2005 | 211 | 0.070 |
Why?
|
| Bradykinin | 1 | 2006 | 42 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2006 | 73 | 0.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 192 | 0.070 |
Why?
|
| Angiotensin II | 1 | 2006 | 86 | 0.070 |
Why?
|
| Patient Care Planning | 2 | 2017 | 139 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 923 | 0.070 |
Why?
|
| Vas Deferens | 1 | 2005 | 16 | 0.060 |
Why?
|
| Digestive System Diseases | 1 | 2005 | 23 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 910 | 0.060 |
Why?
|
| Liver X Receptors | 2 | 2020 | 30 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 179 | 0.060 |
Why?
|
| Genotype | 2 | 2014 | 1760 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2006 | 594 | 0.060 |
Why?
|
| Cells, Cultured | 5 | 2013 | 3881 | 0.060 |
Why?
|
| Gluconeogenesis | 1 | 2005 | 62 | 0.060 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2004 | 10 | 0.060 |
Why?
|
| Europe | 2 | 2016 | 334 | 0.060 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2004 | 17 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 477 | 0.060 |
Why?
|
| Lovastatin | 1 | 2004 | 26 | 0.060 |
Why?
|
| Pancreatitis | 1 | 2005 | 107 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1999 | 395 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2018 | 356 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2008 | 445 | 0.060 |
Why?
|
| Membrane Microdomains | 1 | 2004 | 32 | 0.060 |
Why?
|
| Bronchiectasis | 1 | 2005 | 106 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2010 | 681 | 0.060 |
Why?
|
| beta-Cyclodextrins | 1 | 2004 | 28 | 0.060 |
Why?
|
| Protein Kinases | 2 | 1997 | 307 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1840 | 0.060 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2003 | 3 | 0.060 |
Why?
|
| Receptors, CXCR4 | 1 | 2004 | 78 | 0.060 |
Why?
|
| Collectins | 1 | 2003 | 12 | 0.060 |
Why?
|
| Calreticulin | 1 | 2003 | 24 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 182 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2004 | 217 | 0.060 |
Why?
|
| Chemokines | 4 | 2006 | 216 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 79 | 0.050 |
Why?
|
| Zymosan | 1 | 2023 | 64 | 0.050 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2004 | 95 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2005 | 218 | 0.050 |
Why?
|
| Quality of Life | 1 | 2014 | 2353 | 0.050 |
Why?
|
| Compassionate Use Trials | 1 | 2023 | 8 | 0.050 |
Why?
|
| Leprostatic Agents | 1 | 2022 | 3 | 0.050 |
Why?
|
| Bronchial Provocation Tests | 1 | 2003 | 51 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2003 | 67 | 0.050 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 750 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2003 | 176 | 0.050 |
Why?
|
| Intubation, Intratracheal | 2 | 2006 | 216 | 0.050 |
Why?
|
| Registries | 1 | 2010 | 1767 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2003 | 201 | 0.050 |
Why?
|
| Phosphorylation | 2 | 1997 | 1569 | 0.050 |
Why?
|
| Exhalation | 1 | 2022 | 35 | 0.050 |
Why?
|
| Kinetics | 4 | 2013 | 1551 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2016 | 663 | 0.050 |
Why?
|
| Breath Tests | 1 | 2022 | 82 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2020 | 2565 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2003 | 314 | 0.050 |
Why?
|
| Chemotaxis | 2 | 2004 | 130 | 0.050 |
Why?
|
| Sepsis | 1 | 2007 | 509 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2021 | 34 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 430 | 0.050 |
Why?
|
| Child | 5 | 2021 | 18404 | 0.050 |
Why?
|
| Armadillos | 1 | 2021 | 2 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 1314 | 0.050 |
Why?
|
| Mycobacterium leprae | 1 | 2021 | 7 | 0.050 |
Why?
|
| Clone Cells | 1 | 2021 | 247 | 0.050 |
Why?
|
| CD18 Antigens | 1 | 2000 | 33 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 373 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 165 | 0.050 |
Why?
|
| Bioreactors | 1 | 2021 | 43 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 2020 | 21 | 0.040 |
Why?
|
| Chloroquine | 1 | 2020 | 52 | 0.040 |
Why?
|
| Glycolipids | 1 | 2020 | 35 | 0.040 |
Why?
|
| Liver | 2 | 2005 | 1634 | 0.040 |
Why?
|
| Thiazoles | 2 | 1998 | 110 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 149 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 329 | 0.040 |
Why?
|
| Klebsiella pneumoniae | 2 | 2013 | 41 | 0.040 |
Why?
|
| Proteins | 1 | 2005 | 908 | 0.040 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 1999 | 4 | 0.040 |
Why?
|
| Sirolimus | 1 | 2020 | 181 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 630 | 0.040 |
Why?
|
| Tetraspanin 30 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Apoptosis | 3 | 2013 | 2362 | 0.040 |
Why?
|
| Homozygote | 1 | 2018 | 187 | 0.040 |
Why?
|
| Autophagy | 1 | 2020 | 233 | 0.040 |
Why?
|
| Isoenzymes | 1 | 1999 | 283 | 0.040 |
Why?
|
| Benzodioxoles | 1 | 2018 | 83 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 789 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2279 | 0.040 |
Why?
|
| Cell Migration Inhibition | 2 | 2008 | 13 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 367 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2005 | 1072 | 0.040 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1997 | 19 | 0.040 |
Why?
|
| Pertussis Toxin | 1 | 1997 | 26 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1997 | 43 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1997 | 88 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 372 | 0.040 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1997 | 48 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 581 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1997 | 47 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2016 | 7 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 1313 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2017 | 53 | 0.030 |
Why?
|
| Critical Care | 1 | 2001 | 476 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1996 | 33 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 318 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 870 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 150 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 646 | 0.030 |
Why?
|
| Granuloma | 1 | 2016 | 83 | 0.030 |
Why?
|
| Molecular Weight | 1 | 1996 | 331 | 0.030 |
Why?
|
| Alkylating Agents | 1 | 1996 | 27 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2017 | 233 | 0.030 |
Why?
|
| Insulin | 1 | 2005 | 2076 | 0.030 |
Why?
|
| Chemokine CXCL2 | 2 | 2006 | 41 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 198 | 0.030 |
Why?
|
| Chemokine CXCL1 | 2 | 2006 | 68 | 0.030 |
Why?
|
| Polymyositis | 1 | 1995 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 213 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 1996 | 217 | 0.030 |
Why?
|
| Neonatal Screening | 1 | 2017 | 152 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 270 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2013 | 950 | 0.030 |
Why?
|
| Prednisone | 1 | 1996 | 229 | 0.030 |
Why?
|
| Vasculitis | 1 | 1995 | 66 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 316 | 0.030 |
Why?
|
| Sweat | 1 | 2014 | 38 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1996 | 273 | 0.030 |
Why?
|
| Deoxyribonuclease I | 1 | 2014 | 34 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 1879 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 536 | 0.030 |
Why?
|
| Polysorbates | 1 | 2014 | 35 | 0.030 |
Why?
|
| Paranasal Sinuses | 1 | 2014 | 66 | 0.030 |
Why?
|
| Chlorides | 1 | 2014 | 127 | 0.030 |
Why?
|
| Culture Media | 1 | 2014 | 155 | 0.030 |
Why?
|
| Pregnancy | 1 | 2005 | 5517 | 0.030 |
Why?
|
| Isoniazid | 1 | 2014 | 52 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 287 | 0.030 |
Why?
|
| Hypochlorous Acid | 1 | 2013 | 4 | 0.030 |
Why?
|
| Selenocysteine | 1 | 2013 | 3 | 0.030 |
Why?
|
| Auranofin | 1 | 2013 | 9 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 537 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1997 | 608 | 0.030 |
Why?
|
| Pain | 1 | 1999 | 705 | 0.030 |
Why?
|
| Bronchioles | 1 | 2013 | 22 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 487 | 0.030 |
Why?
|
| Rhinitis | 1 | 2014 | 128 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1842 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 2249 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 120 | 0.030 |
Why?
|
| Cell Line | 2 | 2008 | 2635 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2013 | 352 | 0.030 |
Why?
|
| Peritonitis | 1 | 2013 | 77 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 262 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 1982 | 0.030 |
Why?
|
| Biopsy | 1 | 1996 | 1036 | 0.020 |
Why?
|
| Cysteine | 1 | 2013 | 171 | 0.020 |
Why?
|
| Models, Biological | 1 | 1999 | 1620 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 560 | 0.020 |
Why?
|
| Bone Marrow Cells | 2 | 2004 | 267 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2014 | 285 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 337 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2004 | 9108 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1995 | 620 | 0.020 |
Why?
|
| Genome | 1 | 2013 | 271 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2004 | 1143 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 225 | 0.020 |
Why?
|
| Asthma | 1 | 2003 | 2029 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 975 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 1020 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1394 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1177 | 0.020 |
Why?
|
| U937 Cells | 1 | 2008 | 22 | 0.020 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2008 | 14 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 823 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2008 | 84 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1947 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 736 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2008 | 157 | 0.020 |
Why?
|
| Receptors, Bradykinin | 1 | 2006 | 4 | 0.020 |
Why?
|
| Losartan | 1 | 2006 | 9 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2006 | 52 | 0.020 |
Why?
|
| Aging | 1 | 2016 | 1618 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 75 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2006 | 34 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2006 | 83 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 5043 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2006 | 79 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2006 | 73 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 110 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 728 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 398 | 0.020 |
Why?
|
| Anthracenes | 1 | 2005 | 27 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 4958 | 0.020 |
Why?
|
| Cyclodextrins | 1 | 2004 | 8 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 2005 | 135 | 0.010 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2004 | 34 | 0.010 |
Why?
|
| Monokines | 1 | 2004 | 24 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 371 | 0.010 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2004 | 61 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 74 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2003 | 7 | 0.010 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2003 | 24 | 0.010 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2003 | 29 | 0.010 |
Why?
|
| Complement C1q | 1 | 2003 | 36 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2006 | 807 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 1131 | 0.010 |
Why?
|
| Ambrosia | 1 | 2003 | 7 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2006 | 554 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 2005 | 158 | 0.010 |
Why?
|
| Cell Communication | 1 | 2004 | 279 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2003 | 75 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2003 | 49 | 0.010 |
Why?
|
| Agammaglobulinemia | 1 | 2003 | 30 | 0.010 |
Why?
|
| Ovalbumin | 1 | 2003 | 161 | 0.010 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2004 | 228 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 147 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 367 | 0.010 |
Why?
|
| Interleukin-18 | 1 | 2004 | 219 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 2005 | 373 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 561 | 0.010 |
Why?
|
| Indium Radioisotopes | 1 | 2001 | 13 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 2001 | 12 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 371 | 0.010 |
Why?
|
| Eosinophils | 1 | 2004 | 278 | 0.010 |
Why?
|
| Epitopes | 1 | 2003 | 435 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 386 | 0.010 |
Why?
|
| Immunization | 1 | 2003 | 397 | 0.010 |
Why?
|
| Homeostasis | 1 | 2004 | 573 | 0.010 |
Why?
|
| Inservice Training | 1 | 2001 | 105 | 0.010 |
Why?
|
| Lung Transplantation | 1 | 2001 | 246 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 1889 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 766 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2001 | 517 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 1998 | 445 | 0.010 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 41 | 0.010 |
Why?
|
| Complement C5a | 1 | 1996 | 59 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1996 | 85 | 0.010 |
Why?
|
| Androstadienes | 1 | 1996 | 97 | 0.010 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 1995 | 17 | 0.010 |
Why?
|
| ras Proteins | 1 | 1996 | 138 | 0.010 |
Why?
|
| Capillaries | 1 | 1995 | 91 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2001 | 1700 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1996 | 329 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1996 | 785 | 0.010 |
Why?
|